Search results for "COPD"

Results 1 - 20 of about 22 for "COPD".

Sort by: Relevance | Newest | Oldest

Hyperglycemia risk increased in COPD patients taking glucocorticoids

A systematic review and meta-analysis found that being treated with systemic glucocorticoids for chronic obstructive pulmonary disease (COPD) was associated with more than twofold higher risk for new-onset hyperglycemia versus no glucocorticoid treatment.
https://immattersacp.org/weekly/archives/2024/12/17/4.htm
17 Dec 2024

Antipsychotics associated with risk for acute respiratory failure in older patients with COPD

A case-crossover study of Medicare beneficiaries with chronic obstructive pulmonary disease (COPD) found that risk for acute respiratory failure was higher within 14 days of antipsychotic use and increased with increasing age.
https://immattersacp.org/weekly/archives/2024/12/03/5.htm
3 Dec 2024

Review offers guidance on selecting medications for COPD

Researchers suggest ways for clinicians to assess cognitive function, manual dexterity/strength, and peak inspiratory flow before choosing an inhaled medication delivery system for patients with chronic obstructive pulmonary disease (COPD).
https://immattersacp.org/weekly/archives/2023/11/21/4.htm
21 Nov 2023

Long-term doxycycline may reduce exacerbations for some COPD patients

A randomized trial in the U.K. found that 12 months of doxycycline did not improve chronic obstructive pulmonary disease (COPD) exacerbations overall versus placebo but may have reduced rates in patients with severe disease or lower blood eosinophil counts.
https://immattersacp.org/weekly/archives/2023/07/25/4.htm
25 Jul 2023

Extended-release morphine didn't improve breathlessness in COPD

Patients with chronic obstructive pulmonary disease (COPD) randomized to two different doses of morphine or placebo for three weeks reported similar effects on breathlessness, an Australian trial found. Their step count also didn't change.
https://immattersacp.org/weekly/archives/2022/11/29/1.htm
29 Nov 2022

Race-based spirometry equations may miss emphysema in Black patients

An observational study of Black and White patients who had both spirometry and a CT scan found that emphysema is often present before spirometry results become abnormal, especially in Black men, and that using spirometry alone may overestimate respiratory health.
https://immattersacp.org/weekly/archives/2022/07/19/1.htm
19 Jul 2022

Clinical practice guideline released on pharmacologic management of COPD

The American Thoracic Society strongly recommended LABA/LAMA combination therapy over monotherapy with either agent in patients with chronic obstructive pulmonary disease (COPD) and dyspnea or exercise intolerance, among other guidance.
https://immattersacp.org/weekly/archives/2020/04/21/4.htm
21 Apr 2020

Metoprolol not effective for reducing time to COPD exacerbation

A randomized placebo-controlled trial, which was stopped early due to safety and futility concerns, found no significant between-group difference in median time to first exacerbation of chronic obstructive pulmonary disease (COPD).
https://immattersacp.org/weekly/archives/2019/10/29/4.htm
29 Oct 2019

New model found to help predict 20-year risk of COPD

Prediction of future lung function could let clinicians identify those at high risk for chronic obstructive pulmonary disease (COPD), but the trajectory of lung function decline varies greatly among individuals, the authors noted.
https://immattersacp.org/weekly/archives/2019/10/01/4.htm
1 Oct 2019

Testing CRP level safely reduced antibiotic use in patients with COPD exacerbation

In patients with chronic obstructive pulmonary disease (COPD) exacerbations, point-of-care testing of C-reactive protein (CRP) level decreased antibiotic use without affecting clinical outcomes, a randomized controlled trial found.
https://immattersacp.org/weekly/archives/2019/07/16/1.htm
16 Jul 2019

Triple inhaler therapy associated with reduced COPD exacerbations, higher rates of pneumonia

Results of the systematic review and meta-analysis suggest that triple inhaler therapy should be limited to patients with more severe symptoms of chronic obstructive pulmonary disease (COPD) that cannot be adequately managed by dual therapy, the authors said.
https://immattersacp.org/weekly/archives/2018/11/13/2.htm
13 Nov 2018

LABAs, LAMAs for COPD may be associated with increased CVD risk in first 30 days of use

Study authors caution physicians to closely monitor new users of long-acting beta2-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) for cardiovascular symptoms.
https://immattersacp.org/weekly/archives/2018/01/09/4.htm
9 Jan 2018

Combination treatment for COPD associated with lower rate of exacerbations versus usual care

Patients taking fluticasone furoate-vilanterol had a rate of 1.74 moderate or severe exacerbations per year versus 1.90 per year in the usual care group, an industry-funded trial has shown.
https://immattersacp.org/weekly/archives/2016/09/13/1.htm
13 Sep 2016

Task Force recommends against screening for COPD

The recommendation applies to asymptomatic adults, defined as those who do not recognize or report respiratory symptoms.
https://immattersacp.org/weekly/archives/2016/04/12/4.htm
12 Apr 2016

Low-dose opioids may safely reduce breathlessness in severe COPD

Lower doses of opioids do not appear to increase hospital admissions or death in patients with very severe chronic obstructive pulmonary disease (COPD) and may safely reduce symptoms, according to a new study.
https://immattersacp.org/weekly/archives/2014/02/11/6.htm
11 Feb 2014

Telemonitoring for COPD may not affect exacerbation readmissions, quality of life

Telemonitoring in chronic obstructive pulmonary disease (COPD) patients at high risk for exacerbations did not affect hospital readmissions or improve quality of life, according to a new study.
https://immattersacp.org/weekly/archives/2013/10/29/4.htm
29 Oct 2013

Long-acting beta-agonists and anticholinergics pose similar cardiovascular risks

Patients with chronic obstructive pulmonary disease (COPD) faced increased risk of a cardiovascular event after starting treatment with a long-acting bronchodilator, whether it was a beta-agonist or an anticholinergic, a new study found.
https://immattersacp.org/weekly/archives/2013/06/04/4.htm
4 Jun 2013